amifostine anhydrous has been researched along with Thrombopenia in 19 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In Europe fotemustine (Muphoran) is widely used in the treatment of brain metastases in melanoma patients." | 9.08 | Combined treatment of stage IV melanoma patients with amifostine and fotemustine--a pilot study. ( Breitbart, E; Makki, A; Mohr, P; Schadendorf, D, 1998) |
| " The optimal dosing regimen with amifostine and carboplatin needs to be further evaluated in clinical studies." | 6.40 | Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine. ( Budd, GT; Bukowski, RM; Ganapathi, R; McLain, D; Snyder, J; Wood, L, 1999) |
| "To test the hypothesis that the cytoprotectant amifostine attenuates the thrombocytopenia produced by carboplatin, the authors performed a randomized trial comparing treatment with carboplatin alone versus the combination of amifostine and carboplatin." | 5.08 | Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. ( Adelstein, DJ; Budd, GT; Bukowski, RM; Capizzi, R; Ganapathi, R; McLain, D; Olencki, T; Pelley, R; Petrus, J; Zhang, J, 1997) |
| " In Europe fotemustine (Muphoran) is widely used in the treatment of brain metastases in melanoma patients." | 5.08 | Combined treatment of stage IV melanoma patients with amifostine and fotemustine--a pilot study. ( Breitbart, E; Makki, A; Mohr, P; Schadendorf, D, 1998) |
| " Instead, patients in the control arms of some of the trials have been exposed to more prolonged use or increased dosage of toxic chemotherapy that placed them at greater risk of the toxicity the protective agent was designed to prevent (eg, cardiotoxicity in trials of dexrazoxane, myelosuppression or thrombocytopenia in trials of growth factors)." | 4.80 | Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. ( Phillips, KA; Tannock, IF, 1998) |
| " The optimal dosing regimen with amifostine and carboplatin needs to be further evaluated in clinical studies." | 2.40 | Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine. ( Budd, GT; Bukowski, RM; Ganapathi, R; McLain, D; Snyder, J; Wood, L, 1999) |
| "Thrombocytopenia is a manifestation of hematopoietic toxicity that, at present, can be treated only with platelet transfusions." | 2.39 | Amifostine and chemotherapy-related thrombocytopenia. ( Budd, GT, 1996) |
| " injection of 200 mg/kg WR-2721 at 5 min prior to the administration of this combination enabled us to increase the CBDCA dose from a nontoxic level of 45 mg/kg to a normally toxic dose of 60 mg/kg in non-tumor-bearing BALB/c mice while maintaining the 5FU dose at 100 mg/kg." | 1.28 | Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil. ( Peters, GJ; Treskes, M; van der Vijgh, WJ; van der Wilt, CL; van Laar, JA, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (73.68) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lorusso, D | 1 |
| Ferrandina, G | 1 |
| Greggi, S | 1 |
| Gadducci, A | 1 |
| Pignata, S | 1 |
| Tateo, S | 1 |
| Biamonte, R | 1 |
| Manzione, L | 1 |
| Di Vagno, G | 1 |
| Ferrau', F | 1 |
| Scambia, G | 1 |
| Kalaycioglu, M | 1 |
| Bukowski, R | 1 |
| Budd, GT | 5 |
| Ganapathi, R | 4 |
| Bauer, L | 1 |
| Murthy, S | 2 |
| Adelstein, D | 1 |
| Weick, J | 1 |
| Gibson, V | 1 |
| McLain, D | 3 |
| Sergi, J | 1 |
| Bukowski, RM | 4 |
| Borsi, JD | 1 |
| Csaki, C | 1 |
| Ferencz, T | 1 |
| Oster, W | 1 |
| Adelstein, DJ | 1 |
| Pelley, R | 1 |
| Olencki, T | 1 |
| Petrus, J | 1 |
| Zhang, J | 1 |
| Capizzi, R | 1 |
| Mohr, P | 1 |
| Makki, A | 1 |
| Breitbart, E | 1 |
| Schadendorf, D | 1 |
| Phillips, KA | 1 |
| Tannock, IF | 1 |
| Alberts, DS | 1 |
| Wood, L | 1 |
| Snyder, J | 1 |
| Santini, V | 1 |
| Giles, FJ | 1 |
| Büntzel, J | 1 |
| Glatzel, M | 1 |
| Schuth, J | 1 |
| Weinaug, R | 1 |
| Küttner, K | 1 |
| Fröhlich, D | 1 |
| Johnson, PW | 1 |
| Muers, MF | 1 |
| Peake, MD | 1 |
| Poulter, KM | 1 |
| Gurney, EM | 1 |
| Napp, VV | 1 |
| Hepburn, PM | 1 |
| Brown, JM | 1 |
| Guest, I | 1 |
| Uetrecht, J | 1 |
| Fulda, S | 1 |
| Fichtner, I | 1 |
| Hero, B | 1 |
| Berthold, F | 1 |
| Yavuz, AA | 1 |
| Aydin, F | 1 |
| Yavuz, MN | 1 |
| Ilis, E | 1 |
| Ozdemir, F | 1 |
| van der Wilt, CL | 2 |
| van Laar, JA | 2 |
| Gyergyay, F | 1 |
| Smid, K | 1 |
| Peters, GJ | 2 |
| Treskes, M | 1 |
| van der Vijgh, WJ | 1 |
8 reviews available for amifostine anhydrous and Thrombopenia
| Article | Year |
|---|---|
Clinical status of the new cytoprotective agent, amifostine.
Topics: Agranulocytosis; Amifostine; Antineoplastic Agents; Bone Marrow Purging; Drug Synergism; Granulocyte | 1994 |
Amifostine and chemotherapy-related thrombocytopenia.
Topics: Amifostine; Antineoplastic Agents; Carboplatin; Drug Interactions; Drug Therapy, Combination; Humans | 1996 |
Clinical effects of amifostine (Ethyol) in patients treated with carboplatin.
Topics: Amifostine; Animals; Antineoplastic Agents; Carboplatin; Clinical Trials as Topic; Humans; Mice; Neo | 1996 |
Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy.
Topics: Amifostine; Antineoplastic Agents; Cardiovascular Agents; Clinical Trials, Phase III as Topic; Heart | 1998 |
Protection by amifostine of cyclophosphamide-induced myelosuppression.
Topics: Amifostine; Antineoplastic Agents, Alkylating; Bone Marrow Diseases; Clinical Trials as Topic; Cyclo | 1999 |
Approaches to managing carboplatin-induced thrombocytopenia: focus on the role of amifostine.
Topics: Amifostine; Antineoplastic Agents; Carboplatin; Clinical Trials as Topic; Colony-Stimulating Factors | 1999 |
The potential of amifostine: from cytoprotectant to therapeutic agent.
Topics: Amifostine; Animals; Antineoplastic Agents; Hematologic Neoplasms; Humans; Neutropenia; Radiation-Pr | 1999 |
Bone marrow stem cell protection from chemotherapy by low--molecular-weight compounds.
Topics: Amifostine; Anemia, Aplastic; Antineoplastic Agents; Bone Marrow Cells; Ethylenes; Growth Inhibitors | 2001 |
7 trials available for amifostine anhydrous and Thrombopenia
| Article | Year |
|---|---|
Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Erythrocyte Count; Female; Humans; Infu | 2003 |
Phase I study of WR-2721 and carboplatin.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans | 1993 |
Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents; Bone Marrow; Carboplatin; Female; | 1997 |
Combined treatment of stage IV melanoma patients with amifostine and fotemustine--a pilot study.
Topics: Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Brai | 1998 |
A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Sma | 2001 |
Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
Topics: Adolescent; Amifostine; Animals; Antineoplastic Agents; Bone Marrow Diseases; Carboplatin; Cell Divi | 2001 |
Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Pro | 2001 |
4 other studies available for amifostine anhydrous and Thrombopenia
| Article | Year |
|---|---|
Administration of Ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin.
Topics: Amifostine; Antineoplastic Agents; Carboplatin; Cerebellar Neoplasms; Child; Humans; Male; Medullobl | 1996 |
[Cytoprotection with amifostine in the framework of radiochemotherapy in previously irradiated head and neck carcinoma].
Topics: Adult; Aged; Amifostine; Anemia; Antineoplastic Agents; Brachytherapy; Carboplatin; Combined Modalit | 1999 |
Biochemical modification of the toxicity and the anti-tumour effect of 5-fluorouracil and cis-platinum by WR-2721 in mice.
Topics: Amifostine; Animals; Cisplatin; Colonic Neoplasms; Female; Fluorouracil; Leukopenia; Mice; Mice, Inb | 1992 |
Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil.
Topics: Amifostine; Anemia; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Ne | 1992 |